Your browser doesn't support javascript.
loading
Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
Roque, Dana M; Siegel, Eric R; Buza, Natalia; Bellone, Stefania; Silasi, Dan-Arin; Huang, Gloria S; Andikyan, Vaagn; Clark, Mitchell; Azodi, Masoud; Schwartz, Peter E; Rao, Gautam G; Reader, Jocelyn C; Hui, Pei; Tymon-Rosario, Joan R; Harold, Justin; Mauricio, Dennis; Zeybek, Burak; Menderes, Gulden; Altwerger, Gary; Ratner, Elena; Santin, Alessandro D.
Afiliación
  • Roque DM; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Siegel ER; University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Buza N; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Bellone S; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Silasi DA; Division of Gynecologic Oncology, Mercy Clinic, St. Louis, MO, USA.
  • Huang GS; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Andikyan V; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Clark M; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Azodi M; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Schwartz PE; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Rao GG; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Reader JC; Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
  • Hui P; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Tymon-Rosario JR; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Harold J; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Mauricio D; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Zeybek B; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Menderes G; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Altwerger G; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Ratner E; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA.
  • Santin AD; Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA. alessandro.santin@yale.edu.
Br J Cancer ; 130(6): 1073, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38438590
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Br J Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Br J Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido